Fig. 1

Clinicopathologic evaluation of eIF4A1. A Representative plots show RNA-seq expression profiles of eIF4A1 in naïve B-cells (n = 91) (obtained from DICE database https://dice-database.org/) compared with DLBCL (n = 41) in TCGA dataset. eIF4A1 showed significantly higher expression in tumor samples compared with control. The Y-axis represents transcript per million (TPM) values. ****p < 0.0001. B Comparison of RNA-seq data of eIF4A1 in molecular subgroups using a publicly available large dataset of patients with DLBCL. eIF4A1 showed significantly higher expression in ABC-DLBCL (n = 260) subgroups compared with GCB-DLBCL (n = 138) and UN-DLBCL (n = 104), *p < 0.05. The values are represented in log base 2 of fragments per kilobase of exon per million mapped fragments (FPKM). C Representative immunohistochemistry image of commercially procured (US Biomax., Inc) TMA slides stained with eIF4A1 antibody. Representative scatter plots showing the stained signals of eIF4A1 in reactive LN compared to DLBCL samples. Statistical analysis was performed using Wilcoxon signed-rank test (unpaired two-tailed), ****p < 0.001 vs. reactive LN. Summary chart for DLBCL and normal LN. − ve: no staining detected, low: 1–2 staining density, high: 3–4 staining density. D eIF4A1 expression was found to be significantly (p = 0.039) associated with OS of patients with DLBCL in the publicly available dataset (n = 206). Patients with a lower median expression of eIF4A1 showed a better prognosis than patients having higher median expression. E eIF4A1 expression was also found to be significantly (p = 0.019) associated with the PFS in the same cohort of patients with DLBCL having a similar observation